Get the Stockscreener App
3.955
2.56%
-0.055
Tenax Therapeutics Inc stock is currently priced at $3.955, with a 24-hour trading volume of 15,251.
It has seen a -2.56% decreased in the last 24 hours and a -1.81% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.89 pivot point. If it approaches the $3.98 resistance level, significant changes may occur.
Previous Close:
$3.90
Open:
$3.9
24h Volume:
15,251
Market Cap:
$7.36M
Revenue:
-
Net Income/Loss:
$-7.03M
P/E Ratio:
-1.1949
EPS:
-3.31
Net Cash Flow:
$-7.04M
1W Performance:
+5.56%
1M Performance:
-1.81%
6M Performance:
+1,921%
1Y Performance:
+1,134%
1D Range:
$3.7201
$3.97
52W Range:
$0.151
$21.46
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919 855 2100
Address
ONE Copley Parkway, Suite 490, Morrisville, NC
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
Tenax Therapeutics Inc Stock (TENX) Latest News
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
GlobeNewswire Inc.
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Benzinga
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
GlobeNewswire Inc.
Crude Oil Gains 3%; Kellanova Posts Upbeat Results
Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Tenax Therapeutics Inc Stock (TENX) Financials Data
Tenax Therapeutics Inc (TENX) Net Income 2024
TENX net income (TTM) was -$7.03 million for the quarter ending September 30, 2023, a +39.93% increase year-over-year.
Tenax Therapeutics Inc (TENX) Cash Flow 2024
TENX recorded a free cash flow (TTM) of -$7.04 million for the quarter ending September 30, 2023, a +43.56% increase year-over-year.
Tenax Therapeutics Inc (TENX) Earnings per Share 2024
TENX earnings per share (TTM) was -$92.00 for the quarter ending September 30, 2023, a +84.48% growth year-over-year.
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
1.66%
3.48%
Cap:
|
Volume (24h):